de Silva J A
J Chromatogr. 1985 May 10;340:3-30. doi: 10.1016/0378-4347(85)80193-6.
Therapeutic drug monitoring can involve quantitation in either microgram, nanogram or picogram concentrations present in a complex biological matrix (whole blood, urine or tissue). The chemical structure of a compound influences not only the analytical method best suited to its quantitation, but also its acid/base character (pKa) and its extractability. The dose administered, the bioavailability of the dosage form, and the pharmacokinetic profile of the drug govern the circulating concentrations of either the parent drug and/or its metabolites present in vivo, and dictate the ultimate sensitivity and specificity required of the analytical method. The degree of sample preparation required is dependent on the analytical method used (gas--liquid chromatography, thin-layer chromatography, high-performance liquid chromatography) and on the tolerance of the specific type of detection system to contamination. Factors leading to compound losses during sample preparation (adsorption, stability) are critical at low concentrations and can adversely affect the reliability of an assay, therefore maximizing the overall recovery of the assay is essential not only for high sensitivity but also for good precision and accuracy. Therefore, the criteria to be used in sample preparation should aim to optimize all of the above factors in the overall development of a reliable and validated method for the compound suitable for use in clinical therapeutic monitoring.
治疗药物监测可能涉及对复杂生物基质(全血、尿液或组织)中微克、纳克或皮克浓度的定量分析。化合物的化学结构不仅影响最适合其定量分析的方法,还影响其酸碱特性(pKa)及其可萃取性。给药剂量、剂型的生物利用度以及药物的药代动力学特征决定了体内母体药物和/或其代谢产物的循环浓度,并决定了分析方法所需的最终灵敏度和特异性。所需的样品制备程度取决于所使用的分析方法(气相色谱法、薄层色谱法、高效液相色谱法)以及特定检测系统对污染的耐受性。在样品制备过程中导致化合物损失的因素(吸附、稳定性)在低浓度时至关重要,并且可能对测定的可靠性产生不利影响,因此,提高测定的整体回收率不仅对于高灵敏度至关重要,而且对于良好的精密度和准确性也至关重要。因此,在样品制备中使用的标准应旨在优化上述所有因素,以便全面开发一种适用于临床治疗监测的可靠且经过验证的化合物分析方法。